Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma

  • Technology appraisal guidance
  • TA226
  • Published: 
Download guidance (PDF)

6 Related NICE guidance

Published

  • Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (review of technology appraisal guidance 37). NICE technology appraisal guidance 137 (2008). Available from www.nice.org.uk/guidance/TA137

  • Rituximab for the treatment of follicular lymphoma. NICE technology appraisal guidance 110 (2006). Available from www.nice.org.uk/guidance/TA110

  • Improving outcomes in haematological cancers – the manual. NICE cancer service guidance haemato-oncology (2003). Available from www.nice.org.uk/guidance/CSGHO

Under development

NICE is developing the following guidance (details available from www.nice.org.uk):

  • Rituximab for the treatment of follicular lymphoma (review of technology appraisal guidance 110). NICE technology appraisal. Publication expected December 2011.